Overview
- Editors:
-
-
Gary J. Kelloff
-
Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda
-
Ernest T. Hawk
-
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda
-
Caroline C. Sigman
-
CCS Associates, Mountain View
Access this book
Other ways to access
Table of contents (38 chapters)
-
-
Chemopreventive Agent Development Science
-
-
- John M. Pezzuto, Jerome W. Kosmeder II, Eun-Jung Park, Sang Kook Lee, Muriel Cuendet, Joell Gills et al.
Pages 3-37
-
- Vernon E. Steele, Ronald A. Lubet, Richard C. Moon
Pages 39-46
-
- Ronald A. Lubet, Jeffrey Green, Vernon E. Steele, Ming You
Pages 47-55
-
- Martin Lipkin, Sergio A. Lamprecht
Pages 57-68
-
- Donald Earl Henson, Jorge Albores-Saavedra
Pages 69-96
-
- Robert W. Veltri, Alan W. Partin, M. Craig Miller
Pages 97-108
-
- Robert L. Strausberg, Gregory J. Riggins
Pages 109-114
-
- Melissa A. Troester, Charles M. Perou
Pages 115-122
-
- Emanuel F. Petricoin III, Lance A. Liotta
Pages 123-130
-
-
-
- Sonia de Assis, Peter G. Shields
Pages 141-151
-
- Ian M. Thompson, Charles A. Coltman Jr.
Pages 153-161
-
- Paul P. Carbone, Karen Sielaff, Mary Hamielec, Howard Bailey
Pages 163-179
-
Cancer Chemoprevention at Major Cancer Target Sites
-
Front Matter
Pages 517-517
-
- William G. Nelson, Angelo M. de Marzo, Scott M. Lippman
Pages 185-203
-
- Bulent Akduman, Abelardo Errejon, E. David Crawford
Pages 205-209
-
- Carol J. Fabian, Bruce F. Kimler, Matthew S. Mayo, William E. Grizzle, Shahla Masood, Giske Ursin
Pages 213-237
About this book
Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development—those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can “reasonably predict” clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.
Reviews
"...comprehensive review of the literature concerning current and future cancer chemoprevention strategies... provide(s) a basis for future developments." - The Annals of Pharmacology
"...a good reference source for students and experts alike who are interested in evaluating cancer risk, strategies available to try to prevent certain cancers developing and how the incidence of cancer can be reduced b the use of therapeutic agents. -Newletter of the British Toxicology Society
Editors and Affiliations
-
Biomedical Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda
Gary J. Kelloff
-
Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda
Ernest T. Hawk
-
CCS Associates, Mountain View
Caroline C. Sigman
